Impact of poor glycemic control of type 2 diabetes mellitus on serum prostate-specific antigen concentrations in men

• Published in: Prostate international Vol. 5; no. 3; pp. 104 - 109
• Main Authors: Atalay, Hasan Anıl, Akarsu, Murat, Canat, Lutfi, Ülker, Volkan, Alkan, İlter, Ozkuvancı, Unsal
• Format: Journal Article
• Language: English
• Published: Korea (South) Elsevier B.V 01-09-2017; Asian Pacific Prostate Society; Elsevier
• Subjects: Diabetes mellitus; HbA1c; Original; PSA; HbA1c; Diabetes mellitus; PSA
• ISSN: 2287-8882; 2287-903X
• DOI: 10.1016/j.prnil.2017.02.004

To evaluate the impact of poor glycemic control of type 2 diabetes mellitus (T2DM) on serum prostate-specific antigen (PSA) concentrations in men.
We performed a prospective analysis of 215 consecutive patients affected by erectile dysfunction (ED). ED was evaluated using the IIEF-5 questionnaire and the poor glycemic control (PGC) of T2DM was assessed according to the HbA1c criteria (International Diabetes Federation). Patients were divided into PGC group (HbA1c ≥ 7%) and control group (CG) (HbA1c < 6%). Correlations between serum HbA1c levels and various variables were evaluated and multivariate logistic regression analyses were carried out to identify variables for PGC.
We compared 110 cases to 105 controls men ranging from 44 to 81 years of age, lower PSA concentrations were observed in men with PGC (PGC mean PSA: 0.9 ng/dl, CG mean PSA: 2.1 ng/dl, p < 0.001). Also mean prostate volume was 60% was smaller among men with PGC compared with men with CG (PGC mean prostate volume: 26 ml, CG prostate volume: 43 ml, p < 0.001). A strong negative correlation was found between serum HbA1c levels and serum PSA (p < 0.001 and r = −0.665) concentrations in men with PGC. We also found at the multivariate logistic regression model that PSA, prostate volume and peak systolic velocity were independent predictors of PGC.
Our results suggest that there is significant impact of PGC on serum PSA levels in T2DM. Poor glycemic control of type 2 diabetes was associated with lower serum PSA levels and smaller prostate volumes.